News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ASIT Biotech Announces The Appointment Of Gerd Zettlmeissl As The Company’s New Chairman Of The Board



3/20/2017 9:12:14 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Brussels, Belgium, 20 March, 2017 – 7:30 am – ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces the appointment of Gerd Zettlmeissl as its new Chairman of the Board, Béatrice De Vos having stood down to focus on new projects. Gerd Zettlmeissl, an independent director of ASIT biotech since 2011, was, until that same year, the CEO of Austrian company Intercell AG, an innovative vaccine company that merged with French company Vivalis in 2013 to create Valneva, the European leader in vaccines and antibodies. Mr. Zettlmeissl successfully accompanied Intercell’s international development, and in particular the global registration of a vaccine against Japanese encephalitis and the signing of strategic partnerships with prominent pharmaceutical companies. He holds a doctoral degree in biochemistry from the University of Regensburg, Germany, and did a post-doctoral fellowship in virology at the Institut Pasteur in Paris. Since 1985, Mr. Zettlmeissl has held various R&D and managerial positions at a number of international pharmaceutical companies, and was notably Managing Director of Chiron Behring, a commercial leader in the field of vaccines in Germany. Gerd Zettlmeissl, says: “I am particularly enthusiastic about being able to continue contributing, as Chairman, to the development and future marketing of the next generation of immunotherapy products in order to meet the needs of patients who are seeking significantly less restrictive treatments. I would also like to thank all of the Board’s members, and the ASIT biotech teams, for the trust they have put in me. I firmly believe in the Company’s prospects, and pledge to make the most of my substantial experience in the global development of new therapeutic solutions.” Thierry Legon, CEO of ASIT biotech, adds: “We would like to thank Béatrice De Vos for her remarkable contribution to ASIT biotech’s clinical progress since 2013, the year she was appointed Chairwoman. Her availability and her considerable expertise in terms of the clinical development of drug candidates have been valuable assets for the Company and the success of its IPO in May 2016. We respect her decision, and wish her every success and fulfillment in her future professional and personal projects. Gerd Zettlmeissl’s arrival as Chairman will ensure continuity in the excellence of our governance and the pertinence of ASIT biotech’s strategy, which I firmly believe will enable us to successfully meet the many challenges that await us in 2017 on which we are actively working.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES